Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
By N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. Havel, William Lee, Jianda Yuan, P. Wong, Teresa Ho and 14 more. Science, 2015
6,586 citations recorded by the source corpus.
Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non–small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti–PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy. An anticancer drug is more effective against tumors that carry more mutations. More mutations predict better efficacy Despite the remarkable success of cancer immunotherapies, many patients do not respond to treatment. Rizvi et al. studied the tumors of patients with non–small-cell lung cancer undergoing immunotherapy. In two independent cohorts, treatment efficacy was associated with a higher number of mutations in the tumors. In one patient, a tumor-specific T cell response paralleled tumor regression. Science, this issue p. 124
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d0a5bc5ff2c33c640e97009377304357fe8d2838
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Nicholas McGranahan
- Zena Werb
- Charles Swanton
- Matthew Meyerson
- Stephen J. Elledge
- T. Davoli
- Gad Getz
- M. Lawrence
In Oncology
- J. Wolchok
- Lieping Chen
- Nicholas McGranahan
- W. Zou
- M. Sanmamed
- Antoni Ribas
- Stephen J. Elledge
- Charles Swanton
In Pulmonary and Respiratory Medicine
- Marc Ladanyi
- Mark A. Rubin
- Charles Swanton
- Vincent A. Miller
- Stephen J. Elledge
- Nicholas McGranahan
- J. Luketich
- Pengfei Lu
Citations in the corpus
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “Preliminary evidence emerging from clinical trials of immune checkpoint blockade therapy suggests that high mutation burdens may be predictive of good responses in NSCLC and melanoma [10, 11].”
- PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Similarly, in 29 stage IV NSCLC patients, there were 63% and 0% response rates, respectively,withhigh and lownonsynonymousmutation burden (Table 1) (67).”
- Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018, neutral): “, 2017), neoantigen abundance (Rizvi et al., 2015), MHC class I expression (Marty et al.”